RECURRENT OSTEOSARCOMA

This study tests a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have a specific IDH1 gene change and have either returned or not responded to standard treatments. The goal is to see if the drug can shrink tumors. Only 3 participants were enrolled,…

This study tests whether two immunotherapy drugs, oleclumab and durvalumab, can help people with sarcoma that has come back, spread, or stopped responding to treatment. About 75 adults and some teens (age 12+) with angiosarcoma, dedifferentiated liposarcoma, or osteosarcoma will …

This study tests a drug called larotrectinib in children and young adults (ages 1 to 21) whose advanced or recurrent solid tumors, lymphoma, or histiocytic disorders have a specific genetic change called an NTRK fusion. The drug works by blocking enzymes that help cancer cells gr…

This study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancer has returned or spread and has a specific change in the HRAS gene. The goal is to see if the drug can shrink tumors or stop them from growing. About 5 participants received the drug…

This study tests a drug called cabozantinib in people whose osteosarcoma or Ewing sarcoma has returned or worsened after standard treatment. The drug works by blocking enzymes that help cancer cells grow and by cutting off the blood supply tumors need. The main goal is to see if …

This study tests a humanized antibody (Hu3F8) plus a drug called GM-CSF in people with recurrent osteosarcoma, a type of bone cancer. The goal is to see if this treatment can keep the cancer from coming back after surgery. The trial includes 46 participants aged 1 to 40 who are a…

This study tests a drug called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to standard therapy. The drug works by blocking enzymes that help tumors grow and form blood vesse…

This study tests a drug called selpercatinib in children and young adults (ages 1 to 21) whose cancers have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for patients with advanced solid…

This study tested the drug ensartinib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers had come back or stopped responding to treatment and had specific gene changes (ALK or ROS1). The goal was to see if the drug could shrink o…

This study tests whether adding hydroxychloroquine (a malaria drug) to standard chemotherapy can help control osteosarcoma that has returned or stopped responding to treatment. About 31 participants will receive the drug combination to find the best dose and see if it slows tumor…

This phase 2 trial tests a personalized cell therapy called LN-145 for people with certain advanced cancers (like ovarian, breast, thyroid, or bone cancers) that have not responded to treatment or have returned. The therapy uses a patient's own immune cells, taken from their tumo…

This study tests the drug ulixertinib in about 20 children and teens whose advanced solid tumors, lymphoma, or related blood disorders have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the cancer. Participants must have already …

This early-stage trial tests a personalized cell therapy called GD2CART for children and young adults with osteosarcoma or neuroblastoma that has returned or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to recognize and attack ca…

This study provided a single patient with recurrent osteosarcoma (a type of bone cancer) access to an experimental treatment made from their own tumor's genetic material. The treatment, called RNA-loaded lipid particles (RNA-LPs), was designed to help the immune system fight the …

This study tests a drug called DS-8201a (trastuzumab deruxtecan) in people aged 12 to 39 with HER2-positive osteosarcoma that has returned. The drug works like a smart bomb, attaching to HER2 on cancer cells and delivering chemotherapy directly to them. The main goal is to see if…

This study screens children and young adults (ages 1-21) with advanced solid tumors, lymphomas, or related disorders that have not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be targeted by cert…